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Pseudomonas aeruginosa bacteraemia in an academic 
hospital in South Africa
O Perovic, H J Koornhof, H H Crewe-Brown, A G Duse, W van Nierop, J S Galpin
The incidence of Pseudomonas aeruginosa bacteraemia (PAB) 
has remained stable over the last few decades.1-3  Although 
it is still primarily a nososcomial infection, the number of 
cases of community-acquired bacteraemia caused by this 
organism has increased, notably affecting patients with AIDS4,5 
and neutropenic patients treated for neoplastic disease who 
received outpatient management.6 Predisposing conditions for 
PAB include compromised immunity, neutropenia, intensive 
care, surgical procedures, central venous and urinary catheters 
and previous cephalosporin therapy.1,3-5,6 Common factors 
predictive of a fatal outcome reported in the literature are 
septic shock, neutropenia, immunocompromised state, severe 
underlying disease, and in the elderly pneumonia, septic 
metastases, previous therapy and inappropriate choice of 
antimicrobial drugs for definitive treatment.1,6,7
P. aeruginosa has also emerged as an important bacteraemic 
pathogen in immunocompromised children,6,8,9 including 
very-low-birth-weight infants,9 and as a cause of  community-
acquired pseudomonal sepsis in previously healthy infants and 
children often initially presenting with diarrhoea.10 
During the pre-1990 period when PAB in hospitals peaked, 
improved outcome of this condition was reported widely, e.g. 
PAB mortality declined significantly from 53% to 29% from 
the period 1976 - 1982 to 1992 - 1996.1  Mortality resulting from 
PAB, however, remains high in certain hospital settings, e.g.  
50% in very-low-birth-weight infants,9 33% in AIDS patients in 
a tertiary care hospital, and 39% at a university hospital in the  
early 2000s.7  
Since PAB, including episodes caused by a multidrug-
resistant (MDR) strain, is an important problem at Chris Hani 
Baragwanath Hospital (CHBH), Johannesburg, a clinical 
and epidemiological investigation of PAB was conducted 
in 1998 - 1999. Typing of P. aeruginosa isolates by pulsed-
field gel electrophoresis (PFGE) following chromosomal 
macrorestriction has been shown to be epidemiologically useful 
for strain differentiation,11-13 and this technique was employed 
to investigate P. aeruginosa transmission patterns in the hospital 
setting. 
The study aimed to assess the clinical manifestations, 
outcome and prognostic factors associated with PAB, to 
describe and quantify resistance to antipseudomonal drugs, 
and to perform genotypic characterisation of P. aeruginosa 
isolates causing bacteraemia at CHBH.
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Objectives. The aim of the study was to determine the clinical 
manifestations, outcome of and prognostic factors associated 
with Pseudomonas aeruginosa bacteraemia at Chris Hani 
Baragwanath Hospital, Johannesburg, during the period 1998 - 
1999, to describe and quantify resistance to antipseudomonal 
drugs, to characterise bacteraemic isolates, and to investigate the 
clustering and genotype distribution of drug-susceptible and 
multiply-resistant strains in the hospital.
Methods. Clinical and laboratory investigations, culture 
and antimicrobial susceptibility testing were performed. 
Bacteraemic isolates were typed by endonuclease 
macrorestriction. Those with ≥97% band pattern similarity 
were assigned genotype status.
 Results. Of 91 P. aeruginosa blood isolates, 52 (57.1%) were 
nosocomially acquired. Underlying conditions associated 
with episodes were burns in 24 (28%) and HIV infection in 
21 (24%).  Multidrug resistance was present in 14 (15.4%) of 
isolates from 91 episodes. In 79 episodes where the outcome 
was known, 37 (46.8%) of the patients died. Case fatality 
rates were 75% in adults and 25% in children. Being a child, 
receiving appropriate antimicrobial treatment and admission 
to a specialised care unit were significantly associated with 
improved prognosis. 
Conclusion. P. aeruginosa bacteraemia was associated with 
outbreaks caused by two multiply-resistant genotypes. 
Eighteen antimicrobial-susceptible isolates from bacteraemic 
episodes in paediatric wards, 9 in HIV-seropositive children, 
could be linked to small outbreaks in both hospitalised and 
community-based children. 
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Materials and methods
Setting 
CHBH is a 3 000-bed tertiary care hospital serving an estimated 
1.5 million people, mainly from Soweto, a densely populated 
part of greater Johannesburg, South Africa, mainly inhabited 
by black persons of low socioeconomic status. The hospital 
has surgical, medical and paediatric wards, a large general 
intensive care unit (ICU) and a sophisticated burns centre 
with separate units for paediatric (PBU) and adult (ABU) 
patients. During the study period no antiretroviral treatment 
was available at CHBH and other public hospitals and the 
Annual Antenatal Survey prevalence of HIV among pregnant 
women aged 15 - 24 years was 23% (Department of Health 
– unpublished data).  
Study outline 
This was a retrospective study in which P. aeruginosa isolates 
from blood cultures were collected and stored for future 
analysis.  All patients admitted to CHBH in 1999, as well 
as all adults admitted in 1998 with a positive blood culture 
for PAB, were entered into the study. Records from enrolled 
patients were reviewed. Episodes of PAB were included 
for investigation when the possibility of contamination or 
pseudobacteraemia could be excluded and patients’ clinical 
features were compatible with sepsis. Subsequent episodes 
were recorded in the same patient when the clinical and 
bacteriological response suggested that the previous episode 
had been cured or the organism/s eradicated. All positive 
blood cultures from the same patient obtained within 2 weeks 
of the index culture of an episode were regarded as part of 
the same episode and were kept in reserve but not analysed.  
Polymicrobial episodes were included in the study. All P. 
aeruginosa cultures were tested for antimicrobial susceptibility 
and kept on semi-solid nutrient agar for genetic typing. 
Genotyping of P. aeruginosa isolates was linked to episodes in 
relation to time and patient location in the hospital.  Treatment 
details including duration of antimicrobial administration were 
also available from patients’ records.
Categories and definitions 
By definition an episode of sepsis required at least two of the 
following systemic features in addition to a positive blood 
culture: temperature >38°C or <36°C; pulse rate >90 beats/min; 
respiratory rate >20 breaths/min (adults) and white cell count 
>12×109/l or <4×109/l . PAB acquired 2 days or more after 
admission was defined as nosocomial. 
Microbiology   
Blood samples were processed using the BacT/Alert system 
(Organon Teknika, USA). Sets of aerobic and anaerobic blood 
cultures were processed and incubated routinely for 7 days.
P. aeruginosa was identified according to standard 
microbiological procedures. Susceptibility to 10 single 
antipseudomonal antibiotics (piperacillin, ceftazidime, 
cefepime, imipenem, meropenem, ciprofloxacin, ofloxacin, 
amikacin, gentamicin and tobramycin) and the piperacillin/
tazobactam (PIP/TAZ) combination, all supplied by Mast 
Diagnostics (Mast House, Derby Road, Bootle, UK) was 
determined by the disc diffusion method, minimum inhibitory 
concentration (MIC) and minimum bactericidal concentration 
(MBC) determinations. The micro-dilution method was 
performed according to Clinical Laboratory Standards Institute 
(CLSI)14 criteria. Multidrug resistance (MDR) was defined 
as resistance to two or more classes of antipseudomonal 
agents represented by cephalosporins (ceftazidime and 
fourth-generation cefepime), ureido-penicillins (PIP/TAZ), 
carbapenems, aminoglycosides and fluoroquinolones.
Polymicrobial bacteraemia episodes were recorded when 
additional microbial pathogens together with P. aeruginosa 
were recovered from blood cultures during an episode of 
sepsis. Underlying diseases or conditions associated with PAB, 
including polymicrobial episodes, were noted and included 
burns, HIV infection, haematological malignancies, neonatal 
status, diabetes mellitus and malnutrition. If HIV status was 
not available, clinical criteria (World Health Organization) 
for AIDS were implemented. Underlying factors specific to 
PAB included for analysis were invasive procedures, systemic 
corticosteroid therapy, cytotoxic therapy, surgery, intravascular 
catheters, granulocytopenia and ICU admission. For each 
bacteraemic episode, evidence of localised endogenous sources 
of infection was recorded from patients’ clinical records. More 
than one source per episode was recorded when suggested on 
clinical grounds. 
Antibiotic therapy was considered empiric if it was started 
before the results of cultures and sensitivity testing were 
known and definitive when it was instituted after the P. 
aeruginosa causation and drug susceptibility were established. 
Antimicrobial therapy was defined as appropriate if the strain 
isolated was susceptible to the administered antipseudomonal 
antibiotic/s and the doses and routes of administration were 
adequate. 
Appropriate use of antimicrobial therapy for P. aeruginosa 
bloodstream infections in relation to treatment outcome 
was assessed in patients receiving monotherapy, defined as 
the use of carbapenems, an antipseudomonal β-lactam, a 
fluoroquinolone or an aminoglycoside agent, and in patients 
given combination therapy, comprising an antipseudomonal 
β-lactam agent plus an aminoglycoside or a fluoroquinolone. 
Patients who died within 24 hours of admission were excluded 
from analysis of appropriate use of antimicrobial agents. 
Death was attributed to PAB if clinical deterioration and 
death occurred in the presence of active signs of P. aeruginosa 
infection.
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Epidemiological investigations 
For genotyping, restriction fragment length polymorphism 
(RFLP) of isolate DNA using pulsed-field gel electrophoresis 
(PFGE) was performed. The typing approach used by 
Struelens et al.11 was followed with minor modifications. 
Whole chromosomal DNA in agarose was digested with the 
Xba I enzyme and the restriction fragments separated in a 
CHEF DR II apparatus (Bio-Rad, Richmond, CA). The gel was 
run at 14°C, 6 V/cm and a 120°C switch angle for 18 hours.  
The preparation was then stained with ethidium bromide 
and photographed under ultraviolet illumination to detect 
similarities and differences in banding patterns. 
Statistical analysis 
Logistic regression was used to obtain odds ratios, using 
SPSS statistical software. Other analyses were done using 
contingency tables. 
Similarity between band patterns of isolates was determined 
using a computerised scanner (software, Jelcompar version 4.1; 
Applied Mats-Belgium). Findings were recorded in the form 
of dendrograms exhibiting the degree of similarity between 
isolates expressed in percentages. Strains with similarity of 
97% (3 - 6 band differences) are equivalent to Tenover et al.’s12 
category of ‘possibly related’ strains and isolates within a ≥97% 
similarity cluster were assigned genotype status.11
Results  
Clinical features 
During the 2-year study period P. aeruginosa isolates from 91 
bacteraemic episodes in 86 patients were collected (1 patient 
had three episodes and 3 patients had two separate episodes 
each, all at least 2 weeks apart). Demographic and clinical 
data are presented in Table I, as are underlying conditions that 
potentially contributed to PAB. 
Fifty-seven per cent of  bacteraemic episodes were 
nosocomial and 35.2% community-acquired (unknown 
7.7%). The most common underlying conditions were burns 
(28%), HIV infection (24%), trauma (14%) and haematological 
malignancies (9%).
The probable source of infection was based on clinical 
information from hospital records in 79 episodes (86.8%) 
and unknown in 12 (13.2%). More than a third of episodes 
(35%) were catheter-related. Of the 32 community-acquired 
infections, 15 affected the respiratory tract, 14 with clinical 
features suggesting pneumonia and 1 with chronic obstructive 
pulmonary disease. In contrast, a clinical diagnosis of 
pneumonia accounted for 18 of the 52 nosocomial infections, 
and 11 of these patients required assisted ventilation. Nine 
of the 32 community-acquired infections appeared to have 
an intestinal origin, as evidenced by the development of 
diarrhoea, mainly in children. 
Table I. Demographic and clinical data on 91 episodes of P. aeruginosa bacteraemia (86 patients)
        Children*   Adults   Total
Variables      N (%)   N (%)    N (%)
Patients by gender
Male       20 (23)   27 (31.3)   47 (54.6)
Female      18 (21)   17 (19.7)   35 (40.7)
Unknown           4 (4.6)
   Total       38 (44)   44 (51)   86 (100)
Origin 
Nosocomial      17 (18.6)   35 (38.5)   52 (57.1)
Community-acquired     18 (19.8)   14 (15.4)   32 (35.2)
Unknown     6 (6.6)   1 (1.1)   7 (7.7)
Polymicrobial infection    6 (6.6)   19 (20.9)   25 (27.5)
Outcome (known in 79 patients)   
Death      9 (11.4)   28 (35.4)   37 (46.8)
Survived     25 (31.6)   17 (21.5)   42 (53)
Unknown     6 (7.6)   1 (1.1)   7 (8.8)
Underlying conditions (in 86 patients)
Burns      11 (13)   13 (15)   24 (28)
HIV infection     12 (14)   9 (10)   21 (24)
Haematological malignancies   2 (2.2)   6 (6.8)   8 (9)
Neutropenia      4 (6)   2 (3)   6 (7)
Diabetes     1 (1)   6 (7)   7 (8)
Trauma     2 (2.2)   10 (11.8)   12 (14)
Nosocomial factors    
Surgery     0 (0)   13 (14.2)   13 (14.2)
ICUs†      13 (14)   15 (17)   28 (31)
* < 18 years of age.
† Intensive care units: general, paediatric burns, adult burns.
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A total of 34 bacterial pathogens other than P. aeruginosa 
were identified in 25 polymicrobial episodes (27.5%), all 
nosocomially acquired. There were 7 isolates of Acinetobacter 
baumannii, 7 Staphylococcus spp. (3 methicillin-resistant 
S. aureus (MRSA), 2 methicillin-resistant S. epidermidis 
(MRSE), 2 coagulase-negative staphylococci), 12 members 
of Enterobacteriaceae, 5 Enterococcus spp., 1 group B 
streptococcus, 1 P. rubrum, and 1 viridans streptococcus. 
Of the risk factors that contributed to mortality, 
inappropriate organism-directed treatment was most 
prominent, with a p-value of <0.001. ICU admission was 
associated with a decrease in mortality compared with non-
ICU patients (p<0.001) (Table II). 
Of the 91 isolates, 21 (23.1%) were resistant to the 
antipseudomonal antibiotics tested. CLSI MIC breakpoint 
concentrations showed resistance to individual antibiotics 
to be 16.5% for each of piperacillin and PIP/TAZ, 14.3% for 
cefepime, 13.2% for each of ceftazidime and carbapenems, 4.4% 
for amikacin and gentamicin, and 3.3% for tobramycin, while 
only 1 isolate (1.1%), an untypable MDR strain, was  resistant 
to the fluoroquinolones tested. 
Information relating to organism-directed treatment was 
available for 64 patients. Of those receiving appropriate 
organism-directed therapy, 15 patients on monotherapy 
(75%) survived and 5 (25%) died, while of patients receiving 
combination therapy 17 (81%) survived and 4 (19%) died, 
showing no statistically significant difference. All patients with 
concomitant MRSA/E isolates received vancomycin in addition 
to Pseudomonas cover. Patients who received inappropriate 
monotherapy did poorly and 14 (73.7%) died. Empirical use of 
appropriate antibiotics did not significantly decrease mortality 
(Table II). Organism-directed therapy however, significantly 
decreased mortality (p<0.001) when appropriate antibiotics 
were used (Table II).
Epidemiological findings 
Genetic analysis was performed on 82 P. aeruginosa isolates. 
Pulsed-field gel electrophoresis (PFGE) band patterns of 
isolates from ICU (isolates numbered 1 - 9), ABU (isolates 10 - 
16) and PBU (isolates 17 - 24) are shown in Fig. 1.  A composite 
dendrogram indicating the degree of genetic relatedness of 
isolates from specialised ICUs (labelled 1 - 24) and paediatric 
(labelled P1 - P26), medical (M1 - M23) and surgical wards (S1 
- S11) is shown in Fig. 2. Seven isolates, including one MDR 
isolate from a 62-year-old patient in renal failure, showed poor 
band definition and are not included in the dendrogram.
Thirteen of the 14 MDR isolates were from ICU and PBU 
patients. Eleven of these were linked to two genotypes (clusters 
with ≥97% similarity), accommodating isolates 5, 6, 9, 18, 19 
and 20 in genotype 1 (3 from ICU and 3 from PBU with 99% 
and 100% similarity respectively) and isolates 17, 21, 22, 23 and 
24 in genotype 2 (Table III).  The temporal relationship of MDR 
kb 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 kb
Fig. 1. Macrorestriction analysis of P. aeruginosa isolates from ICU and burns units. Kb-molecular
weight markers from 1 000 kbp to 48.5 kbp. Isolates 1 - 9 were from ICUs, 10 - 17 from the adult burns
unit, and 18 - 24 from the paediatric burns unit.
Fig. 1. Macrorestriction analysis of P. aeruginosa isolates from ICU and 
burns units. Kb-molecular weight markers from 1 000 kbp to 48.5 kbp. 
Isolates 1 - 9 were from ICUs, 10 - 17 from the adult burns unit, and  
18 - 24 from the paediatric burns unit.
Table II. Risk factors for mortality in 91 episodes  
of P. aeruginosa bacteraemia
Risk                        No. of           No. of        OR                  
factors                patients who    deaths       (95% CI)
              survived            p-value
Children*     25      9
Adults     17      28   3.87           0.004
      (1.49 - 10.04)
HIV negative    11      12
HIV positive    8      13   1.49           0.515 
      (0.45 - 4.96) 
Non-surgical    42      29
Surgical      3      10   1.65           0.015 
      (0.66 - 4.14) 
Non-trauma    38      34
Trauma     7      5  0.80            0.720  
      (0.23 - 2.75) 
Non-diabetes    42      35
Diabetes     3      4   1.60            0.553  
      (0.34  - 7.64) 
Community    16      16
Nosocomial    28      23   0.82            0.663 
      (0.34 - 1.99) 
Non-polymicrobial    29      30
Polymicrobial    16      9   0.55            0.210 
      (0.21 - 1.42) 
Non-ICU     22      34
ICUs†     23      5   0.14            <0.001 
      (0.05 - 0.42) 
Antibiotics – organism  
directed 
Appropriate     30      11
Inappropriate     5      18   9.82  
      (2.93 - 32.86)      <0.001
Antibiotics – empirical
Appropriate    8      4   2.09            0.268 
      (0.55 - 7.89) 
Inappropriate    23      24
*<18 years of age.
† Intensive care units: general, paediatric burns, adult burns.
OR = odds ratio; CI = confidence interval.
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genotype clusters expressed in 3-month periods (quarters) is 
shown in Table III. All 14 MDR strains were isolated during 
1999 and with one exception (an adult surgical patient) were in 
the ICU and special burn units. Distinct temporal associations 
can be seen, providing strong evidence of transmission 
involving endemic clones or patient-to-patient transmission. 
Interestingly, a 9-month-old infant whose isolate (number 6) 
belonged to genotype 1 (5, 6, 9, 18, 19, 20) was admitted to the 
PBU on 1 March 1999 and transferred to the ICU on 10 March 
1999, where a blood culture taken 1 day later was positive for 
P. aeruginosa. This isolate was probably acquired in the PBU, as 
were isolates 18, 19 and 20. However, isolate 5 from an 18-year-
old patient in ICU was recovered on the same day as isolate 6, 
suggesting that this genotype was already present in the ICU 
by 11 March 1999.
Eight clusters (genotypes) involving 18 isolates (9 from 
episodes in HIV-seropositive children clinically compatible 
with AIDS) and 2 - 4 isolates per cluster were identified in 
paediatric wards. Most clusters showed temporal associations 
and 3 clusters involved neonates. One community-acquired 
cluster involved 4 infants suffering from AIDS. Four small 
clusters comprising 2 isolates each, all linked by time, were 
demonstrated in medical wards while no clustering was found 
in 7 surgical patients with PAB. 
In paediatric wards 26 PAB isolates were typed. Of these 
isolates, 18 grouped into 8 clusters (genotypes), varying in size 
from 2 to 4 isolates. Two of the 8 clusters included isolates from 
other areas of the hospital (ICU and an adult medical ward). 
Importantly, 16 of the 18 isolates were drug-susceptible (non-
MDR), while 9 of the 18 bacteraemic episodes occurred in HIV-
seropositive children with clinical presentations compatible 
with AIDS. Most clusters developed over relatively short 
periods and 3 clusters occurred in neonates. One hospital-
linked cluster involved 4 infants with AIDS, and their PABs 
were judged to be community-acquired.
Four small clusters comprising 2 isolates each, all temporally 
linked, were demonstrated in medical wards, while no 
clustering was found in 7 surgical patients with PAB. 
Discussion 
Pseudomonas bacteraemia is a major problem at CHBH. In the 
present series of 91 bacteraemic episodes the mortality rate 
was 46.8% for the 79 patients whose outcome was known. In 
a comprehensive review by Maschmeyer and Braveny15 and a 
more recent paper by Kang et al.7 mortality rates of 28% and 
48% respectively were reported.   
Table III. Cluster formation of numbered MDR isolates of P. aeruginosa in specialised units during 1999
Time of          MDR isolates in    Cluster similarity (%) 
   appearance        Genotype 1  Genotype 2 
   (quarters)  ICU PBU ABU   (5, 6, 9, 18, 19, 20)  (15, 16, 17, 21, 22, 23, 24)
1   5, 6 18    5, 6 (99) 
2   9 19, 20    18, 19, 20 (100)
        5, 6, 9, 18, 19, 20 (98) 
3    21 15*, 16*      16*, 21, 23 (99)
           15*, 16*, 23 (98)
4    22, 23, 17       15*, 16*, 17, 21, 22, 23,  
    24       24 (97)
*Isolates 15 and 16 were susceptible to antipseudomonal agents and together with isolate 14, which was genetically unrelated, were recovered from 3 separate bacteraemic episodes in 
the same patient.
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Fig. 2. Dendrogram of percentage similarity among DNA profiles of isolates from all wards during
the study period.
Fig. 2.  Dendrogram of percentage similarity among DNA profiles of 
isolates from all wards during the study period.
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In the present study the age of the patients had an effect on 
outcome and mortality was higher in adult patients (p< 0.001). 
The lower mortality rate of 11.4% in children may be attributed 
to the nature of their underlying conditions, including burns 
and newborn status, where early diagnosis and specialised 
care were more accessible and appropriate antimicrobial 
treatment more likely.  In two university hospitals in Taiwan, 
23% of previously healthy infants and children, who in most 
cases (>70%) initially presented with diarrhoea, died as a 
consequence of P. aeruginosa bacteraemia.10 
In the present study, inappropriate treatment was 
significantly associated with an increased risk of death 
(p<0.001). 
Underlying conditions that contributed substantially to 
deaths from pseudomonas bacteraemia in this study were 
burns (28%) and HIV infection 24% (in 86 patients).  
P. aeruginosa infections are often endemic in burn patients, and 
in a large study a mortality rate of 80% was reported.16 In the 
present study mortality was 36% in burn patients, but only 
14.3% among those admitted to a specialised burns unit. 
The role of P. aeruginosa as an important pathogen in 
children, especially in premature infants, has been known for 
50 years.17 Of the paediatric patients in the present study, 6 
were neonates. In contrast to the report of Tsai et al., none of 
our patients presented with necrotising enterocolitis. Diarrhoea, 
however, reported by others, was noted in community-
acquired PAB in our series.10,18,19 
MDR P. aeruginosa strains were identified in 15.4% of 91 
isolates in our study with evidence of clonal spread in ICU and 
burns units.
Empirical treatment was found not to influence patient 
outcome significantly (p=0.268). There was no statistical 
difference in outcome between patients on appropriate 
monotherapy versus those on appropriate combination 
therapy (p=0.6). Empirical monotherapy with antipseudomonal 
antibiotics was found to have a significant impact on patient 
outcome compared with inappropriate use of a single agent 
(p=0.002). 
For organism-directed therapy, appropriate treatment was 
significantly associated with reduced mortality (p<0.001) 
(Table II). As mentioned above, appropriate monotherapy with 
antipseudomonal drugs was also effective and in the relatively 
small number of cases available for analysis the outcome was 
statistically similar to that of combination therapy with a β-
lactam and aminogycoside.  Published studies indicate that 
combination therapy is not necessarily more advantageous 
than monotherapy, but infectious disease experts still favour 
the use of combination therapy.20,21 
With regard to epidemiological findings, molecular typing 
using PFGE of macrorestriction fragments following digestion 
by Xba I endonuclease producing 25 - 35 fragments in the 10 
- 30 kb range has been used  by Belgian and French workers 
to good effect.13  Spe I endonuclease has been preferred by 
other authors because of slightly superior band separation 
(20 - 25 fragments).12  PFGE of Xba I cut fragments used by 
us proved to be very useful, especially in establishing genetic 
linkage between MDR strains in specialised ICU settings and 
in paediatric wards where genotype analysis produced strong 
evidence of clonal spread either through transmission between 
patients or by means of single-source outbreaks involving 
environmentally derived clones.  For example, MDR strains 
5 and 6 at 99% PFGE similarity were isolated from the ICU in 
March 1999 at the same time as strain 18 from the PBU, which 
was indistinguishable from strains 19 and 20, both isolated in 
May and June 1999 (2nd quarter, see Table III). This cluster, 
which at 98% PFGE similarity also incorporated the MDR 
strain 9 isolated in May 1999, represents an outbreak in infants 
and children in ICU and PBU, caused by an MDR clone over 
a 6-month period. A somewhat different and more complex 
situation applies to the cluster 15, 16, 21, 23 at 98% similarity, 
15 and 16 being susceptible and 21 and 23 multiply resistant. 
Based on epidemiological evidence, this large 7-member cluster 
at 97% similarity, (genotype 2, see Table III) provides evidence 
of another MDR-associated outbreak involving predominantly 
infants and children and may well present an expanded clone 
initially present in ABU as susceptible strains 15 and 16 and 
subsequently as MDR strains in PBU (strains 21, 22 and 23 
showed identical resistance profiles and strain 24 was multiply 
resistant but susceptible to ceftazidime) (Table III).  These 
findings suggest the acquisition and transmission of mobile 
resistance gene cassettes in the form of integrons,22 involving 
the expanded clone (genotype 2).
The presence of MDR strains and evidence of transmission in 
specialised ICU facilities at the hospital suggest that extensive 
use of antimicrobial agents may have played a selective 
role, while prolonged stay in these facilities, especially in 
burns units where wound colonisation with P. aeruginosa was 
common, created ample opportunities for selection of MDR 
strains and transmission. 
Other workers have also studied MDR transmission patterns 
by PFGE typing. Pitten et al.23 described a large outbreak in a 
German academic hospital where all the isolates showed an 
identical band pattern, Richard et al.,24 using PFGE of exotoxin 
A gene, showed that previous treatment with ceftazidime at 
a low dose of 3 g daily in a burns unit was a risk factor for 
MDR emergence, and Hsueh et al.25 described a small outbreak 
caused by a MDR P. aeruginosa clone in an intensive care burn 
unit where the clone persisted in different body sites and 
colonisation was followed by severe PAB in 2 out of 4 patients.
Limitations of our study relate mainly to the retrospective 
retrieval of clinical information and include insufficient data 
on the clinical status of patients and outcome of bacteraemic 
episodes in a few instances and a lack of detailed information 
on previously administered antimicrobial treatment.
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Conclusions
In summary, based on DNA fingerprinting and temporal 
linkage our study provides convincing evidence of nosocomial 
transmission of MDR strains of P. aeruginosa in ICU and PBU. 
Furthermore, we have been able to show endemicity of these 
strains.
The mortality rate of our patients was 46.8 %. As expected, 
failure to employ appropriate organism-directed antibiotic 
treatment produced the poorest outcome (p=0.001). The most 
common underlying conditions in our patients were burns/
trauma and HIV infection. A high number of community-
acquired Pseudomonas infections were noted in this study.
At CHBH clones of MDR P. aeruginosa emerged in children 
hospitalised for prolonged periods, causing outbreaks in 
burns and other ICUs where antimicrobial agents were 
used extensively, while drug-susceptible genotypes caused 
outbreaks in children with AIDS in the hospital and in the 
community.   
We thank the technical support group, M Khoosal and M Kassel, 
for being so helpful, T Gomes for doing PFGE and G Coulson 
for band pattern analysis by software use.  This protocol was 
cleared by the Committee for Research on Human Subjects of the 
University of the Witwatersrand in 1999. 
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